Ratings by Cantor Fitzgerald (Carter Gould)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/13/2026 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/7/2026 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/6/2026 | Amgen | AMGN | Maintain | Neutral (Neutral) |
|
Details | ||
| 7/6/2026 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/6/2026 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/6/2026 | Abbvie | ABBV | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/23/2026 | Pfizer | PFE | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/23/2026 | Abbvie | ABBV | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/22/2026 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/22/2026 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/17/2026 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/16/2026 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/9/2026 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/2/2026 | Merck | MRK | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/1/2026 | Pfizer | PFE | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/18/2026 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/5/2026 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/1/2026 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/8/2026 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/8/2026 | Merck | MRK | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/8/2026 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/8/2026 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/8/2026 | Amgen | AMGN | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/8/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/8/2026 | Abbvie | ABBV | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/6/2026 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/30/2026 | Merck | MRK | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/17/2026 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/25/2026 | Cytokinetics | CYTK | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/13/2026 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2026 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/5/2026 | Abbvie | ABBV | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/5/2026 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/4/2026 | Merck | MRK | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/4/2026 | Amgen | AMGN | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/2/2026 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/23/2026 | Vaxcyte | PCVX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/8/2026 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/1/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/24/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (Neutral) |
|
Details | ||
| 11/20/2025 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/6/2025 | Amgen | AMGN | Maintain | Neutral (Neutral) |
|
Details | ||
| 11/4/2025 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/31/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/29/2025 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/21/2025 | Cytokinetics | CYTK | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/17/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/14/2025 | Abbvie | ABBV | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/9/2025 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/9/2025 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/9/2025 | Abbvie | ABBV | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/30/2025 | Pfizer | PFE | Maintain | Neutral (Neutral) |
|
Details | ||
| 9/18/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/17/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/15/2025 | Abbvie | ABBV | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2025 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2025 | Pfizer | PFE | Maintain | Neutral (Neutral) |
|
Details | ||
| 8/13/2025 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2025 | Amgen | AMGN | Maintain | Neutral (Neutral) |
|
Details | ||
| 8/13/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (Neutral) |
|
Details | ||
| 8/13/2025 | Abbvie | ABBV | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/5/2025 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/31/2025 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/30/2025 | Merck | MRK | Maintain | Neutral (Neutral) |
|
Details | ||
| 7/29/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (Neutral) |
|
Details | ||
| 7/10/2025 | Merck | MRK | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/24/2025 | Amgen | AMGN | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/23/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/12/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/10/2025 | Merck | MRK | Maintain | Neutral (Neutral) |
|
Details | ||
| 6/10/2025 | Vaxcyte | PCVX | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/10/2025 | Pfizer | PFE | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/20/2025 | Pfizer | PFE | Maintain | Neutral (Neutral) |
|
Details | ||
| 5/6/2025 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/2/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/2/2025 | Amgen | AMGN | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/30/2025 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/22/2025 | Eli Lilly | LLY | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/22/2025 | Regeneron Pharma | REGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/22/2025 | Vertex | VRTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/22/2025 | Gilead Sciences | GILD | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/22/2025 | Amgen | AMGN | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/22/2025 | Pfizer | PFE | New Coverage | Neutral (N/A) |
22.04 (25.05) |
13.66% | Details | |
| 4/22/2025 | Merck | MRK | New Coverage | Neutral (N/A) |
77.85 (127.50) |
63.78% | Details | |
| 4/22/2025 | Bristol-Myers Squibb Co. | BMY | New Coverage | Neutral (N/A) |
48.94 (60.74) |
24.11% | Details | |
| 4/22/2025 | Abbvie | ABBV | New Coverage | Overweight (N/A) |
170.16 (254.49) |
49.56% | Details | |
| 4/22/2025 | Vertex | VRTX | New Coverage | Overweight (N/A) |
489.10 (485.65) |
-0.71% | Details | |
| 4/22/2025 | Regeneron Pharma | REGN | New Coverage | Overweight (N/A) |
563.16 (676.69) |
20.16% | Details | |
| 4/22/2025 | Amgen | AMGN | New Coverage | Neutral (N/A) |
277.29 (366.29) |
32.1% | Details | |
| 4/22/2025 | Eli Lilly | LLY | New Coverage | Overweight (N/A) |
839.96 (1179.11) |
40.38% | Details | |
| 4/22/2025 | Vaxcyte | PCVX | New Coverage | Overweight (N/A) |
30.65 (56.20) |
83.36% | Details | |
| 4/22/2025 | Gilead Sciences | GILD | New Coverage | Overweight (N/A) |
104.54 (134.28) |
28.45% | Details |
